• Home
  •  / CSL Behring
ProfileJobs (3.7 k)

CSL Behring

Suggest Edit
Healthcarebiotechdrug developmentpharma

CSL Behring is a provider of life-saving medicines. It develops and delivers a range of medicines to treat disorders such as haemophilia and primary immune deficiencies, and vaccines to prevent influenza. CSL Behring's therapies are also used in cardiac surgery, organ transplantation, and burn treatment.

Revenue(FY, 2020)
$7.9 B

Employee Rating

3.5
TypeSubsidiary
Parent CompanyCSL
HQKing of Prussia, PA, US
Founded1904
Websitecslbehring.com
Cybersecurity ratingBMore
CSL Behring was founded in 1904 and is headquartered in King of Prussia, PA, US
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at CSL Behring

Paul Perreault

Paul Perreault

Chief Executive Officer and Managing Director
Bill Campbell

Bill Campbell

Executive Vice President and Chief Commercial Officer
Paul McKenzie

Paul McKenzie

Chief Operating Officer
Greg Boss

Greg Boss

Executive Vice President Legal and CSL Limited Group General Counsel
Mark Hill

Mark Hill

Chief Digital Information Officer
Elizabeth Walker

Elizabeth Walker

Executive Vice President, Chief Human Resources Officer
Show more

CSL Behring Office Locations

CSL Behring has offices in King of Prussia, Bradley, Kankakee, Broadmeadows and in 27 other locations
King of Prussia, PA, US (HQ)
1020 1st Ave
Bradley, IL, US
1201 N Kinzie Ave
Kankakee, IL, US
P.O. Box 511
Broadmeadows, AU
209 Camp Rd
Parkville, AU
45 Poplar Rd
Parkville, AU
Unit 400/30 Flemington Rd
Show all (37)

CSL Behring Financials and Metrics

Summary Metrics

Founding Date

1904
CSL Behring is a subsidiary of CSL

CSL Behring Revenue

CSL Behring's revenue was reported to be $7.85 b in FY, 2020 which is a 7% increase from the previous period.
USDFY, 2018FY, 2019FY, 2020

Revenue

6.8b7.3b7.9b

Revenue growth, %

8%7%

Gross profit

3.9b4.2b4.5b

Gross profit Margin, %

57%57%58%
show all
USDFY, 2018FY, 2019FY, 2020

Total Assets

10.6b11.2b14.2b

Total Liabilities

6.5b6.7b8.5b
show all
USDFY, 2018

Revenue/Employee

1.6m
Show all financial metrics

CSL Behring Operating Metrics

Dec, 2020

Countries

100

Patent Applications

3

Trademark Applications

1

Trademarks

4

CSL Behring Acquisitions / Subsidiaries

Company NameDateDeal Size
Vitaeris IncJune 08, 2020
CSL Plasma

CSL Behring Revenue Breakdown

Embed Graph

CSL Behring revenue breakdown by business segment: 8.1% from Albumin, 14.3% from Hemophilia, 21.6% from Specialty, 51.1% from Immunoglobulins and 4.8% from Other

CSL Behring Cybersecurity Score

Cybersecurity ratingPremium dataset

B

87/100

Learn more about our premium products
SecurityScorecard logo

CSL Behring Online and Social Media Presence

CSL Behring's Trends

Embed Graph

CSL Behring Company Culture

  • Overall Culture

    D

    57/100

  • CEO Rating

    C-

    63/100

  • Compensation

    C

    62/100

  • Diversity

    D+

    58/100

Learn more on Comparably

CSL Behring News and Updates

December 15, 2021

CSL Behring Receives Accelerated CHMP Assessment for Etranacogene Dezaparvovec for European Patients Living with Hemophilia B

KING OF PRUSSIA, Pa., Dec. 15, 2021 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced that the Committee for Medicinal Products for Human Use (CHMP), the chief scientific body of the European Medicines Agency (EMA) accepted its request for an accelerated assessment...
December 09, 2021

uniQure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B

~ Largest gene therapy study in hemophilia B achieved primary endpoint of non-inferiority in annualized bleeding rate after stable Factor IX (FIX) expression, assessed at 18 months following a single dose of etranacogene dezaparvovec ~
October 25, 2021

HCmed Reaches Milestone in Immunoglobin Combination Product Development with CSL Behring

TAIPEI, Oct. 24, 2021 /PRNewswire/ -- HCmed Innovations (HCmed), a Taiwanese company that focuses on the development of vibrating mesh nebulizers, today announced the successful completion of the first developmental milestone for the collaboration agreement with CSL Behring. Earlier this...
September 04, 2021

CSL Behring Underscores its Commitment to Respiratory Patients with Strong Focus on Research

HATTERSHEIM AM MAIN, Germany, Sept. 4, 2021 /PRNewswire/ -- At this year's fully virtual International Congress of the European Respiratory Society (ERS 2021), CSL Behring will be hosting a highly significant and topical virtual symposium on 6 September 2021, from 20:00 – 21:30 CEST....
June 03, 2021

India Blood Plasma Products Market Report 2021 Featuring Major Global Players - CSL Behring, Grifols, Shire & Octapharma

Dublin, June 03, 2021 (GLOBE NEWSWIRE) -- The "Blood Plasma Products Market in India 2021" report has been added to ResearchAndMarkets.com's offering. The market increased at a CAGR of 11.26% during the FY 2016 - FY 2020 period and is expected to reach INR ~10.43 Bn by FY 2025.
May 14, 2021

Lyfebulb and CSL Behring Announce the Winner of the 2021 Transplant Innovation Challenge

NEW YORK, May 14, 2021 /PRNewswire/ -- Lyfebulb, a patient-empowerment innovation accelerator that bridges the gap between patient communities and the healthcare industry, and CSL Behring, a global biotherapeutics leader driven by its promise to save and improve lives, are excited to...
Show more

CSL Behring Blogs

March 19, 2021

How Students Learn the ABCs of Government

CSL Behring’s Bruce Beatty has given 38 years of volunteer service to a YMCA program designed to teach students how democracy works.
March 18, 2021

Explainer: What Are Natural History Studies?

Natural history studies collect information from patients to better understand diseases, especially rare ones.
March 17, 2021

Being the Match, Saving a Life

Before she became a scientist, Nadia Trejo stepped up to donate her stem cells to a 1-year-old child in need.
March 16, 2021

At the Heart of Innovation for Rare Disease Patients Worldwide

Marburg, Germany’s vibrant R&D ecosystem creates hope for patients and CSL Behring’s future.
March 15, 2021

10 Things to Know About Donating Plasma

Curious to learn more about donating plasma? Here are 10 fast facts.
March 12, 2021

Bringing the World into Focus

For more than 20 years, CSL Behring employee Margaret Anderson has been an advocate for global access to vision care.
Show more

 CSL Behring Frequently Asked Questions

  • When was CSL Behring founded?

    CSL Behring was founded in 1904.

  • Who are CSL Behring key executives?

    CSL Behring's key executives are Paul Perreault, Bill Campbell and Paul McKenzie.

  • How many employees does CSL Behring have?

    CSL Behring has 7,182 employees.

  • What is CSL Behring revenue?

    Latest CSL Behring annual revenue is $7.9 b.

  • What is CSL Behring revenue per employee?

    Latest CSL Behring revenue per employee is $1.1 m.

  • Who are CSL Behring competitors?

    Competitors of CSL Behring include Biotest, Abeona Therapeutics and Octapharma.

  • Where is CSL Behring headquarters?

    CSL Behring headquarters is located at 1020 1st Ave, King of Prussia.

  • Where are CSL Behring offices?

    CSL Behring has offices in King of Prussia, Bradley, Kankakee, Broadmeadows and in 27 other locations.

  • How many offices does CSL Behring have?

    CSL Behring has 37 offices.